Skip to main content

Table 1 Groups of renal cancer cell lines by the promoter methylation status of FLT1 and KDR

From: Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells

Tissue origin

Cell line

Methylation (%)

Group

VEGF

FLT1

KDR

EC

HUVEC

2

1

4

Both low (EC control)

Stomach

SNU1

0

93

83

Both high (cancer cell control)

Lung

H460

0

3

8

Both low (cancer cell control)

Kidney

SNU482

0

4

11

Both low

SNU228

0

2

11

Both low

SN12C

0

65

3

High Flt1/low KDR

SN12PM6

0

45

3

High Flt1/low KDR

A704

0

11

82

Low Flt1/high KDR

ACHN

0

2

70

Low Flt1/high KDR

Caki-1

0

5

49

Low Flt1/high KDR

SNU1272

0

4

39

Low Flt1/high KDR

Caki-2

0

8

25

Low Flt1/high KDR

SNU333

1

80

50

Both high

SNU349

0

89

80

Both high

A498

0

90

36

Both high

SNU267

1

20

37

Both high

  1. EC endothelial cell, HUVEC human umbilical vein endothelial cell, both low low methylation (<15 %) of both FLT1 and KDR, high Flt1/low KDR high methylation (>15 %) of FLT1 and low methylation of KDR, low FLT1/high KDR low methylation of FLT1 and high methylation of KDR, both high high methylation of both FLT1 and KDR